Want to see IN:JAGSNPHARM full AI Analyst Report?
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹282.95
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹15.17B
Enterprise Value₹13.24K
Total Cash (Recent Filing)₹1.06B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)33.9
Beta0.96
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.09%
Share Statistics
EPS (TTM)6.80
Shares Outstanding65,835,470
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and meaningful equity growth give the company durable financial flexibility. This reduces refinancing risk, lowers interest burden and supports funding of working capital, capex or selective M&A without stressing liquidity over the medium term.
Strong Operating MarginsHigh gross and operating margins indicate durable product economics and pricing power in its branded generics/formulations business. Healthy profitability supports reinvestment in sales force, R&D and distribution, underpinning sustainable cash generation.
Solid Cash GenerationRecent strong cash conversion and near-par free cash flow to earnings improve funding capacity for growth and shareholder returns. Reliable cash generation reduces dependence on external financing and enhances ability to absorb medium-term demand swings.
Bears Say
Earnings VolatilityProfitability has fluctuated year-to-year despite revenue re-acceleration, undermining predictability of earnings and returns. This makes forecasting, capital allocation and investor assessment harder and raises execution risk over the medium term.
Choppy Cash Conversion HistoryAlthough recent cash conversion is strong, past swings driven by working-capital timing mean free cash flow can be inconsistent. This variability can force short-term financing or deferment of investments and weakens reliability of cash for dividends or buybacks.
Concentrated Domestic Branded-Generics ExposureDependence on Indian branded generics and a domestic sales/distribution footprint concentrates revenue risk. Competitive pricing, regulatory actions or shifts in prescription patterns in core markets could materially affect growth and make revenue streams less diversified.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹282.95 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹15.17B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 97 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Jul 29, 2026. The company reported ₹2.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹4 which represents an annual dividend yield of 1.09%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 65,835,470 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹2.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.902%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spans three primary therapeutic domains: women's health, pain management and analgesia, and general medical care. Within general medicine, the company offers solutions for allergy control, immune and cellular protection, gastrointestinal and mental wellness, anti-infectives, and products specifically for dental and ear, nose, and throat (ENT) conditions. For women's healthcare, their offerings include pregnancy support and treatments for issues related to dysfunctional uterine bleeding. Furthermore, Jagsonpal provides medications for pain relief and skeletal and joint health. These pharmaceutical items are supplied in common forms like tablets, capsules, and syrups. The company operates as a subsidiary under Aresko Progressive Private Limited.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―